Sign in to continue:

Sunday, April 19th, 2026

Executive Compensation and Ownership Disclosure for Fiscal Year 2025 – SEC Filing Overview

Affinity Bancshares, Inc. Files Amended 10-K/A — Key Details for Investors

Affinity Bancshares, Inc. (NASDAQ: AFBI) has filed an Amendment No. 1 (10-K/A) to its Annual Report for the fiscal year ended December 31, 2025. This amendment provides investors and shareholders with critical updates and required disclosures, especially regarding executive compensation, corporate governance, and equity ownership. Below are the essential highlights and what shareholders should be aware of:

Key Points in the Report

  • Nature of Amendment: The amendment is solely to provide additional information required by Part III of the original 10-K. It specifically includes details on directors, executive officers, corporate governance, executive compensation, security ownership, and related transactions. Importantly, the amendment does not alter any previously reported financial statements or other disclosures in Parts I or II.
  • Corporate Structure & Listing:

    • Business Address: 3175 Highway 278, Covington, GA 30014
    • Listed on The NASDAQ Stock Market LLC under the symbol AFBI
    • Common Stock, par value \$0.01 per share
    • As of March 31, 2026, 6,094,885 shares of common stock are outstanding
    • Public float (non-affiliate shares) as of June 30, 2025: \$96.8 million (at \$18.38 per share)
  • Regulatory Compliance:

    • AFBI is an accelerated filer (not a large accelerated filer, smaller reporting company, emerging growth company, or shell company)
    • The company has filed all required SEC reports in a timely manner and submitted all Interactive Data Files as required
  • Corporate Governance and Ethics:

    • A Code of Ethics is in place for principal executive, financial, and accounting officers. This is available on the company’s website.
    • The company has a comprehensive Insider Trading Policy for directors, officers, and employees, filed as an exhibit with this report.
    • There is no policy restricting employees or directors from hedging or offsetting transactions in the company’s equity securities, which some investors may view as a potential governance concern.
    • Audit Committee: The Board has adopted a written charter for the Audit Committee, available on the company’s website. The Audit Committee met four times in 2025.
  • Executive Compensation Highlights (2025):

    • Edward J. Cooney, President & CEO:

      • Salary: \$463,500
      • Stock Awards: \$0
      • All Other Compensation: \$146,794 (includes \$1,290 life insurance premiums, \$14,631 automobile allowance, \$12,250 ESOP, \$21,000 other compensation, \$7,200, \$13,935, \$76,488, and \$107,984 in various benefits/compensation—see detailed table in the report)
    • Clark N. Nelson, EVP & Chief Credit Officer:

      • All Other Compensation: \$63,839 (details not fully itemized in excerpt; refer to full report for breakdown)

    Note: There were no stock or option awards granted in 2025 to top executives, and compensation is heavily weighted towards salary and other benefits.

  • Equity Awards:

    • The report includes a table of Outstanding Equity Awards at Fiscal Year End for named executive officers, detailing unexercised options and unvested stock awards, and their fair value as of December 31, 2025.
  • Section 16(a) Compliance:

    • All executive officers, directors, and 10% beneficial owners were in compliance with timely filings of ownership reports as required by the SEC.
  • Audit Committee Financial Expertise:

    • The company states that each Audit Committee member is financially literate and has assessed finances and financial reporting for his own business interests.
  • Shareholder Recommendations & Related Party Transactions:

    • No changes to procedures for shareholders to recommend director nominees.
    • Related party transactions and director independence are addressed in the amendment.

Important & Potentially Price-Sensitive Issues

  • No Changes to Financial Statements or Results: The amendment does not alter previously reported results or financials. Investors should not expect new disclosures that directly impact earnings, asset quality, or capital.
  • Executive Compensation Structure: The lack of equity awards or stock-based compensation for executives in 2025, with compensation heavily weighted towards salary and “all other compensation,” could be scrutinized by shareholders and governance-focused investors.
  • Governance Note: The absence of a policy prohibiting hedging by employees and directors may be viewed negatively by investors concerned with alignment between management and shareholder interests.
  • Audit & Compliance: Full compliance with SEC reporting and Section 16(a) requirements is a positive for investor confidence.

Summary for Investors

While this 10-K/A amendment does not introduce new financial results or material operational developments, it provides a comprehensive update on governance, compliance, and executive compensation. There are no obvious restatements, error corrections, or financial surprises. However, the details on compensation structure, the absence of equity incentives, and lack of a hedging policy are noteworthy for investors evaluating governance and long-term alignment of interests.

Share price implications are likely limited in the absence of new financial information, but governance and compensation details may influence sentiment among institutional shareholders and proxy advisors.


Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Investors should review the full 10-K/A and consult with their financial advisors before making any investment decisions.

View Affinity Bancshares, Inc. Historical chart here



Valmont Industries, Inc. Form 8-K Filing Details, Company Information, and XBRL Data (March 3, 2026)

Valmont Industries, Inc. Files 8-K: Dismissal of Independent...

Iterum Therapeutics plc Form 8-K Filing: Company Details, Delisting Notice, and NASDAQ Information (Feb 24, 2026)

Iterum Therapeutics Faces Nasdaq Delisting: Key Details for ...